Prescription of heroin for the management of heroin dependence: Current status

CNS Drugs

Volumn 23, Issue 6, 2009, Pages 463-476

  Lintzeris, Nicholas ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZODIAZEPINE; BUPRENORPHINE; DIAMORPHINE; METHADONE; TRICYCLIC ANTIDEPRESSANT AGENT;

BRAIN HYPOXIA; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG ABUSE PATTERN; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG UTILIZATION; ERYTHEMA; EUROPE; FATIGUE; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; HYPOXIA; LOW DRUG DOSE; MEMORY DISORDER; MENTAL CONCENTRATION; MUSCLE TWITCH; NAUSEA; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SELF REPORT; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL STATUS; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNITED KINGDOM; VISUAL IMPAIRMENT; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

COST-BENEFIT ANALYSIS; HEROIN; HEROIN DEPENDENCE; HUMANS; NARCOTICS; OUTCOME ASSESSMENT (HEALTH CARE); PRESCRIPTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 66749139110     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923060-00002     Document Type: Review

References (66)

1. United Nations Office on Drugs and Crime. World drug report. Vol. 1: analysis [online]. Available from URL: http://www.unodc.org/pdf/WDR-2006/ wdr2006-volume1.pdf [Accessed 2009 Mar 27]
2. Teesson M, Ross J, Darke S, et al. One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 2006; 83: 174-80
3. Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361: 662-8
4. Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326: 959-60
5. Mayet S, Farrell M, Ferri M, et al. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2005 Jan 25; (1): CD004330
6. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2002; (2): CD001333
7. Farrell M, Ward J, Mattick R, et al. Methadone maintenance treatment in opiate dependence: a review. BMJ 1994; 309: 997-1001
8. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-190
9. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; (2): CD002207
10. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003; (2): CD002209
11. Ward J, Mattick R, Hall W, et al. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers, 1998
12. Gossop M, Marsden J, Stewart D, et al. Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2000; 60: 275-86
13. Strang J, Gossop M, editors. Heroin addiction and drug policy: the British system. Oxford: Oxford University Press, 1994
14. Strang J, Sheridan J. Heroin prescribing in the 'British System' of the mid 1990s: data from the 1995 national survey of community pharmacies in England and Wales. Drug Alcohol Rev 1997; 16: 7-16
15. Strang J, Manning V, Mayet S, et al. Does prescribing for opiate addiction change after national guidelines? Me-thadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995-2005. Addiction 2007; 102: 761-70
16. Fischer B, Oviedo-Joekes E, Blanken P, et al. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health 2007; 84 (4): 552-62
17. Klous MG, Van den Brink W, Van Ree JM, et al. Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend 2005; 80: 283-95
18. Rook E. Pharmacokinetics and pharmacodynamics of dia-cetylmorphine in opioid dependent patients. Utrecht: Uni-versteit Utrecht, Faculteit Geneeskunde, 2004
19. Comer SD, Collins ED, Macarthur RB, et al. Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology 1999; 143: 327-38
20. Mitchell TB, Lintzeris N, Bond A, et al. The feasibility and acceptability of an intranasal diamorphine spray as an alternative to injectable diamorphine for maintenance treatment. Eur Addict Res 2006; 12: 91-5
21. Hendriks VM, Van den Brink W, Blanken P, et al. Heroin self-administration by means of 'chasing the dragon': pharmacodynamics and bioavailability of inhaled heroin. Eur Neuropsychopharmacol 2001; 11: 241-52
22. Inturrisi CE, Max MB, Foley KM, et al. The pharmaco-kinetics of heroin in patients with chronic pain. N Engl J Med 1984; 310: 1213-7
23. Gyr E, Brenneisen R, Bourquin D, et al. Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program. Int J Clin Pharmacol Ther 2000; 38: 486-91
24. Metrebian N, Carnwath T, Stimson GV, et al. Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction 2002; 97: 1155-61
25. Sell L, Zador D. Patients prescribed injectable heroin or methadone: their opinions and experiences of treatment. Addiction 2004; 99: 442-9
26. Battersby M, Farrell M, Gossop M, et al. "Horse trading". Prescribing injectable opiates to opiate addicts: a descriptive study. Drug Alcohol Rev 1992; 11: 35-42
27. Metrebian N, Carnwath Z, Mott J, et al. Patients receiving a prescription for diamorphine (heroin) in the United Kingdom. Drug Alcohol Rev 2006; 25: 115-21
28. UK Health Departments. Drug misuse and dependence: guidelines on clinical management: update 2007. London: The Stationery Office, 2007
29. Gschwend P, Rehm J, Blattler R, et al. Dosage regimes in the prescription of heroin and other narcotics to chronic opioid addicts in Switzerland-Swiss National Cohort Study. Eur Addict Res 2004; 10: 41-8
30. van den Brink W, Hendricks VM, Blanken P, et al. Medical co-prescription of heroin: two randomised controlled trials. Utrecht: Central Committee on the Treatment of Heroin Addicts (CCBH), 2002
31. Haasen C, Verthein U, Degkwitz P, et al. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2007; 191: 55-62
32. March JC, Oviedo-Joekes E, Perea-Milla E, et al. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006; 31: 203-11
33. OFSP. Manuel Traitement avec prescription d'heroine: directives, recommandations, informations. Berne: 7 Office Federal de la Sante Publique, 2001
34. Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2004; (4): CD004147
35. Zador D, Lintzeris N, van der Waal R, et al. The fine line between harm reduction and harm production: development of a clinic policy on groin injecting. Eur Addict Res 2008; 14: 213-8
36. Buster M, Rook L, van Brussel GH, et al. Chasing the dragon, related to the impaired lung function among heroin users. Drug Alcohol Depend 2002; 68: 221-8
37. Frick U, Rehm J, Kovacic S, et al. A prospective cohort study on orally administered heroin substitution for severely addicted opioid users. Addiction 2006; 101: 1631-9
38. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev 2005; (2): CD003410
39. Hartnoll R, Mitcheson M, Battersby A, et al. Evaluation of heroin maintenance in controlled trials. Arch Gen Psychiatry 1980; 37: 877-83
40. Perneger TV, Giner F, del Rio M, et al. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-8
41. van den Brink W, Hendriks VM, Blanken P, et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 2003; 327: 310-6
42. NAOMI: North America's first heroin prescription program introduced in Canada [online]. Available from URL: http://www.worldpress.org/Americas/2054.cfm [Accessed 2009 Mar 27]
43. Lintzeris N, Strang J, Metrebian N, et al. Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct J 2006; 3: 28-33
44. Uchtenhagen A, Dobler-Mikola A, Steffen T, et al. Prescription of narcotics for heroin addicts: main results of the Swiss national cohort study. New York: Karger, 1999
45. Stimson GV, Oppenheimer E. Heroin addiction: treatment and control in Britain. London: Tavistock, 1982
46. Metrebian N, Shanahan W, Wells B, et al. Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions. MJA 1998; 168: 596-600
47. Blanken P, Hendriks VM, Koeter MW, et al. Matching of treatment-resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials. Addiction 2005; 100 (1): 89-95
48. Verthein U, Bonorden-Kleij K, Degkwitz P, et al. Long-term effects of heroin-assisted treatment in Germany. Addiction 2008; 103 (6): 960-6
49. Guttinger F, Gschwend P, Schulte B, et al. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addict Res 2003; 9 (2): 73-9
50. Dijkgraaf MG, van der Zanden BP, de Borgie CA, et al. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomized trials. BMJ 2005; 330: 1297-300
51. Bammer G. Provision of diamorphine (heroin) by prescription for drug dependency: issues and recommendations. CNS Drugs 1999; 11: 253-62
52. Rehm J, Frick U, Hartwig C, et al. Mortality in heroin-assisted treatment in Switzerland 1994-2000. Drug Alcohol Depend 2005; 79: 137-43
53. Dursteler-MacFarland KM, Stohler R, Moldovanyi A, et al. Complaints of heroin-maintained patients: a survey of symptoms ascribed to diacetylmorphine. Drug Alcohol Depend 2006; 81: 231-9
54. Hug I. Epileptiform activity in opiate-dependent patients on intravenous substitution treatment with heroin, morphine and methadone [in German; medical thesis]. Basel: University of Basel, 1997
55. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill Inc., 1996: 521-55
56. Dursteler-MacFarland KM, Stormer R, Seifritz E, et al. Opioid-associated effects on oxygen saturation in humans. Addiction 2000; 95: 285-7
57. Stoermer R, Drewe J, Dursteler-MacFarland K, et al. Safety of injectable opioid treatment in addiction: a controlled clinical trial. Biol Psychiatry 2003; 54: 854-61
58. Lintzeris N, Mitchell T, Strang J, et al. Risk factors for oxygen desaturation after injection of heroin or metha-done: a laboratory model of overdose susceptibility [poster presentation]. CPDD; 2008 Jun 19; San Juan
59. Hock C, Stormer R, Dursteler K, et al. Heroin-induced deoxygenation of cerebral hemoglobin: monitoring by means of near-infrared spectroscopy. Ann Neurol 1999; 45: 134-5
60. Ladewig D, Dursteler-MacFarland KM, Seifritz E, et al. New aspects in the treatment of heroin dependence with special reference to neurobiological aspects. Eur Psychiatry 2002; 17: 163-6
61. Hartwig C, Haasen C, Reimer J, et al. Pregnancy and birth under maintenance treatment with diamorphine (heroin): a case report. Eur Addict Res 2008; 14 (2): 113-4
62. Fountain J, Strang J, Gossop M, et al. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 2000; 95: 393-406
63. Bammer G, van den Brink W, Gschwend P, et al. What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug Alcohol Rev 2003; 22: 363-71
64. Paterson S, Lintzeris N, Mitchell TB, et al. Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence. Addiction 2005; 100: 1832-9
65. Zador D. Injectable opiate maintenance in the UK: is it good clinical practice? Addiction 2001; 96: 547-53
66. Wodak A. The current status of heroin prescription treatment for heroin dependence. Expert Opin Drug Saf 2005; 4: 815-9